Research Progress of Aβ Targeting PET Imaging Agents for Alzheimer’s Disease

doi:10.7538/tws.2018.youxian.013

Abstract

Abstract:

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in central nervous system. The diagnosis of AD is mainly based on pathological examination after death, which shows no value to the treatment of AD. If identified and intervened as early as possible at presymptomatic states, the progression of the disease may be delayed. With the progress of positron emission tomography (PET) imaging in clinic, the diagnosis of AD at the early stage with noninvasive techniques become possible. Extracellular senile plaques (SPs), made of accumulations of β-amyloid (Aβ), is one of the most important neuropathological hallmarks of AD. Aβ targeting PET imaging agents are of great significance to early diagnosis of AD, and are one research focus in this field. The research progress of Aβ imaging agents with a small organic molecule is reviewed, which include several kinds: congo red derivatives, aminonaphtyl derivatives, benzothiazole derivatives, benzothiazole-analogues derivatives, stilbene derivatives, substituted-stilbene derivatives and other derivatives. The ideal characteristics of Aβ imaging agents are summarized, and the trend for developing Aβ imaging agents is discussed.

Key words: Alzheimer’s disease (AD), positron emission tomography (PET), A&beta, imaging

摘要：

阿尔茨海默病（AD）是一种进行性中枢神经退行性疾病，其确诊主要依据死亡后的病理学检查，但对治疗已无意义，只有早期诊断并干预，才能取得较好的治疗效果。正电子发射断层显像（PET）技术的发展，为早期非侵入性诊断AD提供了可能性。β淀粉样蛋白（Aβ）沉积形成的胞外老年斑沉积（SPs）是AD的重要病理学特征之一，以Aβ为靶点的PET显像剂对AD早期诊断具有重要意义，也是该领域的研究热点。本文介绍了有机小分子类Aβ显像剂的研究进展，主要包括刚果红类、氨基萘类、苯并噻唑类、苯并噻唑衍生类、二苯乙烯类、取代二苯乙烯类和其他有机小分子，总结了Aβ显像剂的理想特征并对Aβ显像剂的发展进行了展望。

关键词: 阿尔茨海默病（AD）, 正电子发射断层显像（PET）, Aβ显像剂

LI Zhongyong;CUI Haiping. Research Progress of Aβ Targeting PET Imaging Agents for Alzheimer’s Disease[J]. Journal of Isotopes, 2020, 33(1): 27-37.

李忠勇;崔海平. 以Aβ为靶点的阿尔茨海默病PET显像剂的研究进展[J]. 同位素, 2020, 33(1): 27-37.

References

［1］Citron M. Alzheimer’s disease: strategies for disease modification［J］. Nature Reviews Drug Discovery, 2010, 9(5): 387-398.
［2］Trojanowski J Q, Clark C M, Schmidt M L, et al. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer’s disease［J］. Neurobiology of Aging, 1997, 18(S4): S75-S79.
［3］McKhann G M, Knopman D S, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease［J］. Alzheimer’s & Dementia, 2011, 7(3): 263-269.
［4］Albert M S, DeKosky S T, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease［J］. Alzheimer’s & Dementia, 2011, 7(3): 270-279.
［5］Sperling R A, Aisen P S, Beckett L A, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease［J］. Alzheimer’s & Dementia, 2011, 7(3): 280-292.
［6］王武尚,张锦明,刘伯里. AD脑Aβ放射性显像剂的研究进展［J］. 同位素,2004,11(4):232-240.Wang Shangwu, Zhang Jinmming, Liu Boli. Progress of radioactive imaging agent of amyloid in the brain with Alzheimer’s disease［J］. Journal of Isotopes, 2004, 11(4): 232-240(in Chinese).
［7］Hardy J A, Higgins G A. Alzheimer’s disease: the amyloid cascade hypothesis［J］. Science, 1992, 256(5 054): 184-185.
［8］Hardy J, Selkoe D J. The amyloid hypothesis of alzheimer’s disease: progress and problems on the road to therapeutics［J］. Science, 2002, 297(5 580): 353-356.
［9］陈祥纪. β-淀粉样斑块显像剂的研究［J］. 化学进展,2007,19(1):123-129.Chen Xiangji. Advances in imaging agents for βamyloid plaques［J］. Progress in Chemistry, 2007, 19(1): 123-129(in Chinese).
［10］Klunk W E, Bacskai B J, Mathis C A, et al. Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered congo red derivative［J］. Journal of Neuropathology and Experimental Neurology, 2002, 61(9): 797-805.
［11］Wang Y M, Mathis C A, Huang G F, et al. Synthesis and ¹¹C-labelling of (E,E)-1-(30,40-dihydroxystyryl)-4-(30-methoxy-40-hydroxystyryl) benzene for PET imaging of amyloid deposits［J］. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45(8): 647-664.
［12］Kumar P, Zheng W Z, McQuarrie S A, et al. ¹⁸F FESB: synthesis and automated radiofluorination of a novel ¹⁸F-labeled PET tracer for β-amyloid plaques［J］. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48(13): 983-996.
［13］Leung K. 2-(1-{6-［(2-［18F］Fluoroethyl)(methyl)amino］-2-naphthyl}ethylidene)malononitrile ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2005［2011-06-26］. https:∥www.ncbi.nlm.nih.gov/books/NBK23038/.
［14］Agdeppa E D, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission eomography imaging probes for β-amyloid plaques in Alzheimer’s disease［J］. The Journal of Neuroscience, 2001, 21(24): RC189.
［15］Leung K. N-Methyl［¹¹C］-2-(4′-methylaminophenyl)-6-hydroxybenzothiasole ［M/OL］. Bethesda (MD): National Center for Biotechnology-Information (US), 2005［2005-07-25］. https:∥www.ncbi.nlm.nih.gov/books/NBK23443/.
［16］Andersson J D, Varnas K, Cselenyi Z, et al. Radiosynthesis of the candidate β-Amyloid radioligand ［¹¹C］AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys［J］. Synapse, 2010, 64(10): 733-741.
［17］Johnson A E, Jeppsson F, Sandell J, et al. AZD2184: a radioligand for sensitive detection of amyloid deposits［J］. Journal of Neurochemistry, 2009, 108: 1177-1186.
［18］Chopra A.2-{3-［¹⁸F］Fluoro-4-(methylamino)phenyl}-1,3-benzothiazol-6-ol-［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2012［2012-12-27］. https:∥www.ncbi.nlm.nih.gov/books/NBK115136/.
［19］Chopra A. ¹⁸F-Labeled 6-methyl-2-(4′-fluorophenyl)-1,3-benzothiazole ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2009［2009-01-07］. https:∥www.ncbi.nlm.nih.gov/books/NBK23586/.
［20］Chopra A. ¹⁸F-Labeled 6-amino-2-(4′-fluorophenyl)-1,3-benzothiazole and other derivatives ［M/OL］. 2010［2010-01-07］. Available from: https:∥www.ncbi.nlm.nih.gov/books/NBK23100/.
［21］Serdons K, Verduyckt T, Vanderghinste D, et al. Synthesis of ¹⁸F-labelled 2-(40-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with ［¹¹C］PIB［J］. Bioorganic & Medicinal Chemistry Letters, 2009, 19(3): 602-605.
［22］Serdons K, Terwinghe C, Vermaelen P, et al. Synthesis and evaluation of ¹⁸F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer’s disease［J］. Journal of Medicinal Chemistry, 2009, 52(2): 1428-1437.
［23］Serdons K, Laere K V, Janssen P, et al. Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents［J］. Journal of Medicinal Chemistry, 2009, 52(22): 7090-7102.
［24］Andersson J D, Varnas K, Cselenyi Z, et al. Radiosynthesis of the candidate β-amyloid radioligand ［¹¹C］AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys［J］. Synapse, 2010, 64(10): 733-741.
［25］Nyberg S, Jonhagen M E, Cselenyi Z, et al. Low background and high contrast PET imaging of amyloid-β with ［¹¹C］AZD2995 and ［¹¹C］AZD2184 in Alzheimer’s disease patients［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40(4): 580-593.
［26］Leung K. ［¹¹C］2-(2-［2-Dimethylaminothiazol-5-yl］ethenyl)-6-(2-［fluoro］ethoxy)benzoxazole ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2007［2008-08-26］. https:∥www.ncbi.nlm.nih.gov/books/NBK23213/.
［27］Jureus A, Swahn B M, Sacdell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand［J］. Journal of Neurochemistry, 2010, 114(3): 784-794.
［28］Cselenyi Z, Jonhagen M E, Forsberg A, et al. Clinical validation of ¹⁸F-AZD4694, an amyloid-β-specific PET radioligand［J］. Journal of Nuclear Medicine, 2012, 53(3): 415-424.
［29］Rowe C C, Pejoska S, Mulligan R S, et al. Head-to-head comparison of ¹¹C-PIB and ¹⁸F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia［J］. Journal of Nuclear Medicine, 2013, 54(6): 1-7.
［30］Cheng Y, Ono M, Kimura H, et al. A novel ¹⁸F-labeled pyridyl benzofuran derivative for imaging of β-amyloid plaques in Alzheimer’s brains［J］. Bioorganic & Medicinal Chemistry Letters, 2010, 20: 6141-6144.
［31］Leung K. ［S-methyl-¹¹C］N,N-Dimethyl-4-(6-(methylthio)imidazo［1,2-a］pyridine-2-yl)aniline ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2007［2007-11-19］. https:∥www.ncbi.nlm.nih.gov/books/NBK23405/.
［32］Zeng F X, Southerland J A, Voll R J, et al. Synthesis and evaluation of two ¹⁸F-labeled imidazo［1,2-a］pyridine analogues as potential agents for imaging b-amyloid in Alzheimer’s disease［J］. Bioorganic & Medicinal Chemistry Letters, 2006, 16(11): 3015-3018.
［33］Hostetler E D, Sanabria-Bohorquez S, Fan H, et al. ［¹⁸F］Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey［J］. Nuclear Medicine & Biology, 2011, 38(8):1193-1203.
［34］The MICAD Research Team. ［¹¹C］4N-Methylamino-4′-hydroxystilbene ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2005［2005-03-03］. https:∥www.ncbi.nlm.nih.gov/books/NBK23321/.
［35］Leung K. Trans-4-(N-Methylamino)-4′-{2-［2-(2-［¹⁸F］fluoro-ethoxy)-ethoxy］-ethoxy}-stilbene-［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US),2009［2009-06-05］. https:∥www.ncbi.nlm.nih.gov/books/NBK23203/.
［36］Leung K. (E)-4-(2-(6-(2-(2-(2-(［¹⁸F］-fluoroethoxy)ethoxy)ethoxy)pyridine-3-yl)vinyl)-N-methylbenzenamine ［M/OL］. Bethesda (MD): National Center for Biotechnology Information (US), 2010［2010-12-9］. https:∥www.ncbi.nlm.nih.gov/books/NBK32300/.
［37］Lee I, Choe Y S, Choi J Y, et al. Synthesis and evaluation of ¹⁸F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging［J］. Journal of Medicinal Chemistry, 2012, 55(2): 883-892.
［38］Lee H J, Jeong J M, Rai G, et al. ¹⁸F Labeled benzylideneaniline derivatives as new ligands for β-amyloid plaque imaging in Alzheimer’s disease［J］. Nuclear Medicine and Biology, 2009, 36(2): 107-116.
［39］Zhuang Z P, Kung M P, Kung H F. Synthesis of biphenyltrienes as probes for β-amyloid plaques［J］. Journal of Medicinal Chemistry, 2006, 49(9): 2841-2844.
［40］Chandra R, Oya S, Kung M P, et al. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques［J］. Journal of Medicinal Chemistry, 2007, 50(10): 2415-2423.
［41］Qu W C, Choi S R, Hou C, et al. Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for β-amyloid plaques［J］. Bioorganic & Medicinal Chemistry Letters, 2008, 18(17): 4823-4827.
［42］Qu W C, Kung M P, Hou C, et al. Quick assembly of 1,4-diphenyltriazoles as probes targeting β-amyloid aggregates in alzheimer’s disease［J］. Journal of Medicinal Chemistry, 2007, 50(14): 3380-3387.
［43］Chandra R, Kung M P, Kung H F. Design, synthesis, and structure-activity relationship of novel thiophene derivatives for β-amyloid plaque imaging［J］. Bioorganic & Medicinal Chemistry Letters, 2006, 16(5): 1350-1352.
［44］Zhuang Z P, Kung M P, Hou C, et al. Biphenyls labeled with technetium 99m for imaging β-amyloid plaques in the brain［J］. Nuclear Medicine and Biology, 2005, 32(2): 171-184.
［45］Ono M, Watanabe R, Kawashima H, et al. ¹⁸F-labeled flavones for in vivo imaging of β-amyloid plaques in Alzheimer’s brains［J］. Bioorganic & Medicinal Chemistry, 2009, 17(5): 2 0692 076.
［46］Ono M, Watanabe R, Kawashima H, et al. Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of β-amyloid plaques in Alzheimer’s disease［J］. Journal of Medicinal Chemistry, 2009, 52(20): 6394-6401.
［47］Ono M, Haratake M, Mori H, et al. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains［J］. Bioorganic & Medicinal Chemistry, 2007, 15(21): 6802-6809.
［48］Ryu E K, Choe Y S, Lee K H, et al. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging［J］. Journal of Medicinal Chemistry, 2006, 49(20): 6111-6119.
［49］Shimadzu H, Suemoto T, Suzuki M, et al. A novel probe for imaging amyloid-β: synthesis of F-18 labelled BF-108, an acridine orange analog［J］. Journal of Labelled Compounds, 2003, 46(8): 765-772.
［50］Duan X H, Qiao J P, Yang Y. et al. Novel anilinophthalimide derivatives as potential probes for β-amyloid plaque in the brain［J］. Bioorganic & Medicinal Chemistry, 2010, 18(3): 1337-1343.
［51］Mathis C A, Mason N S, Lopresti B J, et al. Development of positron emission tomography β-amyloid plaque imaging agents［J］. Seminars in Nuclear Medicine, 2012, 42(6): 423-432.
［52］Kung H F, Choi S R, Qu W C, et al. ¹⁸F Stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimer’s disease: a miniperspective［J］. Journal of Medicinal Chemistry, 2010, 53(3): 933-941.

[1]	HE Yulin;LIU Ziyu;WANG Wenrui;JIA Kaili;WANG Xiangcheng;WANG Xuemei. Automatic Synthesis of Myocardial Perfusion Imaging Agent ¹⁸F-BMS747158-02 and Imaging of Myocardial Ischemia Model [J]. Journal of Isotopes, 2020, 33(6): 417-422.
[2]	LIU Jingru;ZHU Hong. Research Progress of Radionuclide-Labeled PSMA Ligands in the Diagnosis and Treatment of Prostate Cancer [J]. Journal of Isotopes, 2020, 33(4): 241-249.
[3]	HUANG Qianhuan;XU Yuping;YANG Min. PET Image Developments for HER2-Positive Breast Cancer [J]. Journal of Isotopes, 2019, 32(6): 431-438.
[4]	ZHANG Jinming;DU Jin. Preparation of Radiopharmaceuticals in China: Current Status and Prospects [J]. Journal of Isotopes, 2019, 32(3): 178-185.
[5]	WANG Rongfu;WU Caixia. The Clinical Application Value of Radionuclides and Radiolabeled Compounds [J]. Journal of Isotopes, 2019, 32(3): 195-203.
[6]	GAO Hang;ZHANG Huabei. Research Progress of Radioligands for α7 Nicotinic Acetylcholine Receptor [J]. Journal of Isotopes, 2019, 32(3): 218-230.
[7]	WEN Fuhua;ZHANG Zhanwen;Ma Hui;ZHANG Dake;TANG Ganghua. Full Automated Synthesis of ¹⁸F-FDOPA and Preliminary PET/CT Imaging [J]. Journal of Isotopes, 2018, 31(5): 269-275.
[8]	LIU Bingnan;XIONG Liping;JIANG Shende;YAO Shaobo. Synthesis of 16-Epiestriol and its Radiolabeling Procedure [J]. Journal of Isotopes, 2018, 31(5): 283-290.
[9]	MA Jingxin;WU Zhou;JIANG Shende;WANG Hongliang;WU Zhifang. Synthesis and Biological Evaluation of 3-O-(2-¹⁸F-fluoroethyl)-L-DOPA as A Potential PET Agent for Tumor Imaging [J]. Journal of Isotopes, 2018, 31(5): 310-317.
[10]	LI Liqiang;WANG Feng;LIU Teli;ZHU Hua;YANG Zhi. Production of Iodine-124 and Its Application in PET Molecular Imaging [J]. Journal of Isotopes, 2018, 31(3): 188-197.
[11]	TANG Ganghua. Compound Molecular Probe and Imaging [J]. Journal of Isotopes, 2018, 31(1): 48-56.
[12]	DAI Tiantian;WEI Qingyang. Advantages and Disadvantages of the Lutetium-176 Intrinsic Radiation in the PET System [J]. Journal of Isotopes, 2018, 31(1): 26-32.
[13]	LIU Yinli;LI Zhongyong. Preparation of ¹⁸F-Labeled Styryl Nitrogenous Heterocycles [J]. Journal of Isotopes, 2018, 31(1): 33-41.
[14]	YAN Fu-qin;ZHOU Wei-hua;SUN Xiao-meng;LIU Xiao-jun. The Synthesis and Evaluation of ¹¹C-KW6002 as the PET Adenosine 2A Receptor Imaging Agent [J]. Journal of Isotopes, 2017, 30(3): 204-208.
[15]	YANG Chun-hui;LIANG Ji-xin;SHEN Lang-tao;LI Hong-yu. Progress of Preparation and Applications of ⁶⁸Ga-Labelled Radiopharmaceuticals [J]. Journal of Isotopes, 2017, 30(3): 209-218.